Funding for this research was provided by:
National Institutes of Health (R01AG049402)
Alzheimer's Association (AARF-17-504483)
Received: 8 March 2019
Accepted: 5 June 2019
First Online: 27 June 2019
: All animal experiments were approved by the ethical committee of Columbia University (IACUC #: AC-AAAO5301 and AC-AAAQ5429).
: Not applicable.
: OA is a founder of Neurokine Therapeutics. OA has received research funding from Appia Pharmaceuticals LLC. EA, EKA, MVdB, WG, MF, AS, EC, EZ, LD, SXD, PD, and JF declare that they have no competing interests.